Slide 1: FY'12 Results Conference Call
FY’12 RESULTS Conference Call
Slide 2: Highlights
HIGHLIGHTS
Slide 3: Main Topics
MAIN TOPICS Boosting revenues of tests based on CLIA technology ex Vitamin D (+14% in FY’12 and +19% in Q4’12) Worldwide success attributed to the LIAISON XL from customers: • LIAISON XL placements in key countries: • +477 in 2012 • +125 in Q4’12 • set the basis for a positive effect on the future r
Slide 4: FY'12 Revenues
FY’12 REVENUES Q4’12 FY’12 vs. vs. Q4’11 FY’11 CLIA ex Vitamin D sales up +14% in FY’12 and +19% in Q4’12 Vitamin D pricing pressure, offsetting growth from other CLIA products in FY’12 @ current +0.8% -1.4% FY’12 Q4’12 results showing SALES a positive change in trend of sales (+0.8%) @ CER -0.6% -4
Slide 5: Revenues: Breakdown by Technology
REVENUES: BREAKDOWN BY TECHNOLOGY Q4’12 vs. FY’12 vs. Q4’11 FY’11 Double-digit growth confirmed in FY’12 CLIA ex VIT D +19.1% +13.7% Boosting growth in Q4’12 CLIA ex Vit D revenues surpassing VIT D Sales in absolute value Negative effect mainly due to pricing VIT D -13.5% -13.8% pressure, especially
Slide 6: Revenues: Breakdown by Geography (1 of 2)
REVENUES: BREAKDOWN BY GEOGRAPHY (1 OF 2) Q4’12 vs. FY’12 vs. Q4’12 vs. FY’12 vs. Q4’11 FY’11 Q4’11 FY’11 Strong Europe +6.7% +1.2% Germany +8.6% +5.7% and steady growth CLIA ex Vit D up in FY’12 France -2.1% -8.5% and in Q4’12, offset by Vitamin D price pressure Strong performance, Italy +4.9% +0.1
Slide 7: Revenues: Breakdown by Geography (2 of 2)
REVENUES: BREAKDOWN BY GEOGRAPHY (2 OF 2) Q4’12 vs. FY’12 vs. Q4’12 vs. FY’12 vs. Q4’11 FY’11 Q4’11 FY’11 Steady and impressive growth across all menu Apac +27.0% +19.1% China +29.0% +26.0% LIAISON XL successful launch in Dec 2012 CLIA ex Vit D business developed from scratch, with sales consistentl
Slide 8: Installed Base Enlargement
INSTALLED BASE ENLARGEMENT Total units New units New units Total units at Dec 31, 2011 in 2012 Q4'12 at Dec 31, 2012 4,078 + 57 + 10 4,135 128 + 477 + 125 605 TOTAL 4,206 + 534 + 135 4,740 8
Slide 9: Profitability Profile
PROFITABILITY PROFILE Q4’12 Q4’11 FY’12 FY’11 EBITDA margin 36.0% 40.7% 39.7% 43.2% - 350 bps GROUP MARGINALTY DRIVEN BY: Reagents ex Vitamin D confirming the 2011 steady and high margin levels - Vitamin D pricing pressure affecting negatively reagents marginality as predicted ~ 250 bps High instrum
Slide 10: Business Development
BUSINESS DEVELOPMENT 10
Slide 11: Immunodiagnostics
BUSINESS DEVELOPMENT Clinical Area # test Test Instruments family Measles IgM Infectious 4 Mumps IgM Diseases CMV IgG Avidity(*) Toxo IgG Avidity(*) Helicobacter Pylori Gastrointestinal 2 Clostridium Difficile GDH Infections Immunodiagnostics Hypertension 1 Aldosterone Hepatitis 2 HTLV I-II and Retr
Slide 12: FY'12 Financials
FY’12 FINANCIALS 12
Slide 13: FY'12 Results: Income Statement
FY’12 RESULTS: INCOME STATEMENT Full Year Change €/mln 2012 2011 Amount % Net Revenues 433.8 440.0 -6.2 -1.4% Gross profit 297.3 313.9 -16.5 -5.3% Gross margin 68.5% 71.3% S&M (82.1) (78.0) -4.1 +5.2% R&D (23.4) (21.5) -1.9 +8.9% G&A (48.2) (45.9) -2.2 +4.9% Total operating expenses (153.7) (145.4)
Slide 14: FY'12 Results: Balance Sheet
FY’12 RESULTS: BALANCE SHEET €/mln 12/31/2012 12/31/2011 Total intangible assets 125.3 121.9 Total tangible assets 65.3 62.7 Other non-current assets 21.3 20.7 Net Working Capital 137.6 133.9 Other non-current liabilities (28.6) (29.7) Net Capital Employed 320.9 309.5 Net Financial Position 47.2 41.
Slide 15: FY'12 Results: Cash Flow Statement
FY’12 RESULTS: CASH FLOW STATEMENT €/mln 12/31/2012 12/31/2011 Change in value Cash and cash equivalents at beginning of period 64.1 62.4 +1.7 Operating activities 110.6 108.6 +2.0 Financing activities (32.3) (79.3) +47.0 Investing activities (30.3) (27.5) -2.8 M&A (7.6) - -7.6 Net Change in net cas
Slide 16: FY 2013 Guidance
FY 2013 GUIDANCE Revenues: growth between +2% and +4% at CER vs. FY’12 revenues; molecular revenues representing ~ € 5 mln EBITDA: in line with the absolute value of 2012 at CER, with an absorption from Molecular business equal to ~ € 6 mln, as a result of investments required in the development of
Slide 17: Ordinary Dividend
ORDINARY DIVIDEND Ordinary dividend: Shareholders’ Meeting convened for: Apr 22, 2013 (first calling) Apr 24, 2013 (second calling) to vote on a motion to distribute an ordinary dividend AMOUNT: 0.50 euros per share Total amount: 27,176,628.50 euros, calculated on 54,353,257 shares, not counting the